Venture.med is an MCP server that gives AI agents access to healthcare capital markets — deal flow, pipeline verification, investor mapping, startup benchmarks. Connect your agent, ask a question, get verified data.
Venture.med MCP Server
Venture.med is an MCP server that gives AI agents direct access to healthcare capital market data — deal flow, investor mapping, pipeline verification, startup benchmarking. One endpoint, multiple intelligence layers.
82% of VCs already use AI for deal sourcing. But PitchBook costs $12-70K/year, Crunchbase has no healthcare focus, and none of them offer agent-native interfaces. Venture.med fills that gap — connecting deal data with verified clinical pipelines in a single query.
// Agent discovery GET https://venture.med/.well-known/mcp { "server": "venture.med/mcp/v1", "tools": ["search_deals", "verify_pipeline", "map_investors", "benchmark_startup", "track_company", "regulatory_alerts"], "sources": ["ClinicalTrials.gov", "SEC EDGAR", "openFDA", "EMA"], "verified": true }
Your agent asks: "Show me all mRNA Series A rounds in the last 90 days." Venture.med returns structured results — startup, funding amount, lead investor, valuation — filtered by segment, stage, geography, and timeframe. No PitchBook license needed.
A startup claims 3 Phase II programs. Your agent cross-checks against ClinicalTrials.gov in real time. How many registered studies? Which indications? Any discrepancies? This is the killer feature — no other deal intelligence tool does this.
Which VCs have invested in RNA delivery in the last 12 months? Who's done repeat investments in mRNA therapeutics? Venture.med maps investors to clinical specialties — a view that takes days of manual research elsewhere.
Preparing for a Series A? Get anonymized comps: average valuations in your segment, typical team size at funding stage, median pipeline depth. Data that costs $25K+/year on PitchBook — available through a single agent query.
Put any healthcare startup on a watchlist. Your agent gets notified when they file new trials, announce funding, publish papers, or change leadership. Continuous monitoring instead of periodic manual checks.
FDA guidance changes, EMA scientific advice, new clinical trial requirements — filtered for your therapeutic segment. Phase III delays cost $600K-$8M per week. Early detection saves millions.
See it in action
Click a tool to see the agent query and its visual output side by side.
| PitchBook | Crunchbase | Venture.med | |
|---|---|---|---|
| Price | $12K-$70K/year | $49-$99/month | Free tier + token-based |
| Interface | Web dashboard | Web + basic API | MCP endpoint for AI agents |
| Healthcare focus | General + HC filter | None | Healthcare-native |
| Pipeline verification | Not available | Not available | Auto-verified via ClinicalTrials.gov |
| Deal + clinical linked | Manual | Not possible | Single query |
| Agent-native | No | No | Built for MCP |
Domain Portfolio
Each domain comes with a complete strategy package — technical architecture, detailed use cases, financial projections, and go-to-market plan. You're not buying a URL. You're acquiring a fully documented business opportunity.
The mRNA clinical data interface. 970+ active programs, FDA approvals, and pipeline intelligence for AI agents.
The umbrella interface for all RNA therapeutics. siRNA, mRNA, ASO, RNA editing — one unified endpoint.
Cross-venture portfolio intelligence for healthcare studios. Pipeline tracking, LP reporting, white-space analysis.
Why .med
Only verified healthcare entities can register .med domains. In the agent economy, the domain is the credential — not just a name.
.med requires verification. When an AI agent queries venture.med, it knows the source is a legitimate healthcare entity. No other TLD offers this.
The Model Context Protocol uses .well-known endpoints. A .med domain with a verified MCP server becomes the default trusted source for medical AI agents.
Market timing
Oct 2025
40,000+ pre-registrations. Healthcare-restricted namespace goes live.
Nov 2025
$20B company validates the domain-as-agent-interface model.
2026
Anthropic, Google, IBM backing MCP. Healthcare agents need trusted data interfaces.
2027+
Network effects compound. First movers own the namespace. The window closes.
Venture.med is currently in private beta. Request access for your AI agent — or inquire about acquiring one of our portfolio domains.
Brands & Projects
nextbusiness.ai, Venture.med, mRNA.med, RNA.med, and VentureBuilder.med are brands and projects of Noorder partners GmbH.
www.noorder.de
Noorder partners GmbH
Neubertstraße 36
22087 Hamburg, Germany
Contact
E-Mail: martin@noorder.partners
Represented by
Martin Zielinski, Managing Director
Commercial register
Amtsgericht Hamburg · HRB 187434
VAT ID
DE368890023
EU Dispute Resolution
Online dispute resolution: ec.europa.eu/consumers/odr
We are not willing or obliged to participate in dispute resolution proceedings before a consumer arbitration board.
Liability for content
As a service provider, we are responsible for our own content on these pages in accordance with general legislation. We are not obligated to monitor transmitted or stored third-party information. Upon becoming aware of legal violations, we will remove such content immediately.
Copyright
Content created by the site operators is subject to German copyright law. Reproduction, processing, distribution, and exploitation beyond the limits of copyright require written consent of the respective author.
We take the protection of your personal data seriously. We treat your personal data confidentially and in accordance with applicable data protection regulations.
1. Responsible party
Noorder partners GmbH
Neubertstraße 36, 22087 Hamburg
E-Mail: martin@noorder.partners
2. Hosting and server log files
The hoster automatically collects information in server log files that your browser transmits: browser type and version, operating system, referrer URL, hostname, time of server request, IP address. This data is not merged with other data sources. Collection is based on Art. 6 (1) lit. f GDPR (legitimate interest in technically error-free presentation of the website).
3. Cookies
This website may use cookies to increase usability and security. You can configure your browser to reject cookies.
4. Contact
When you contact us by e-mail, the data you provide will be stored to process your inquiry. We delete this data after storage is no longer required, or restrict processing if statutory retention obligations exist.
5. Your rights
You have the right at any time to free information about your stored personal data, its origin and recipients, and the purpose of data processing, as well as a right to correction or deletion. Contact us at martin@noorder.partners for any data protection inquiries.
Last updated: March 2026
970+ active mRNA programs. $185 billion projected market by 2030. The pharma industry drowns in fragmented data across ClinicalTrials.gov, openFDA, PubMed, and EMA — all with different APIs, formats, and access methods. Here's what you can build on mRNA.med.
The market opportunity
What you can build
Run an MCP server on mRNA.med. Every agent request is metered. Free tier for adoption, Pro at $0.002/request, Enterprise with SLA. The same model OpenAI and Perplexity use at scale. Infrastructure costs start at ~€30/month.
Biotech CI teams spend weeks and six-figure budgets gathering data manually. An mRNA.med endpoint delivers automated daily competitor monitoring — new clinical trials, FDA status changes, publication alerts — in seconds instead of weeks.
Healthcare VCs spend 40-100 hours per deal on technical due diligence. An agent connected to mRNA.med verifies pipeline claims against ClinicalTrials.gov automatically. At $29.3M average deal size, the ROI of one better call is enormous.
Phase III delays cost $600K-$8M per week. mRNA.med can deliver regulatory intelligence filtered specifically for mRNA programs. Earlier detection shortens submission timelines by weeks.
Aggregated usage data creates a unique dataset about AI demand in healthcare. Anonymized quarterly reports for pharma, investors, and regulators at $10K-$50K per edition.
Revenue projection (conservative)
siRNA. mRNA. ASO. RNA editing. Four modalities, one $26B+ market — and no single interface covering them all. RNA.med is the broadest keyword in the most valuable therapeutic category, inside a healthcare-restricted namespace. Here's what you can build.
The strategic position
What you can build
The only interface covering all RNA therapeutics in one endpoint. While competitors build modality-specific tools, RNA.med captures the entire category. As the market converges, the umbrella position becomes exponentially more valuable.
Corporate strategy and BD teams evaluating licensing, M&A, and portfolio decisions need cross-modality views. RNA.med delivers the full picture — not siloed datasets. Even a 1% improvement on a $1B deal is $10M in value.
Real-time data across all RNA modalities: program distribution, indication concentration, funding trends, new launches. Subscription-based at $1K-$5K/month for continuous access.
RNA.med provides market context for mRNA.med clinical data and Venture.med capital intelligence. It's the connective tissue — and can take a transaction fee on cross-interface queries.
Why RNA.med
RNA.com isn't available. RNA.health doesn't carry healthcare verification. RNA.med exists in a restricted namespace where only verified healthcare entities can register — and in the agent economy, the domain is the credential.
Flagship Pioneering created Moderna. Redesign Health has launched 58+ ventures. 129 healthcare venture studios worldwide — and none have a dedicated intelligence platform. Here's what you can build on VentureBuilder.med.
The market
What you can build
Studios running 3-15 companies need one view, not fifteen dashboards. VentureBuilder.med aggregates pipeline data, funding status, and competitive positioning across an entire portfolio. Enterprise SaaS at $2K-$10K/month per studio.
Quarterly LP reports take weeks of manual compilation. An agent on VentureBuilder.med generates them with verified pipeline data — not self-reported metrics. This alone justifies the subscription.
Which RNA indications aren't covered by any portfolio venture? Where are competitive overlaps? Systematic gap analysis replacing $50K-$200K strategy consulting engagements.
Pharma BD teams need visibility into studio portfolios for partnership decisions. VentureBuilder.med becomes the marketplace — taking commission on facilitated deals. One Flagship-style partnership can generate $500M+ in licensing value.
VentureBuilder.med is the capstone connecting clinical data (mRNA.med), market intelligence (RNA.med), and capital flows (Venture.med). Whoever controls this aggregation layer shapes the healthcare venture ecosystem.
API Reference
Four tools, one endpoint. Connect your AI agent to venture.med/.well-known/mcp and start querying healthcare capital market data with verified clinical pipeline cross-referencing.
Search for healthcare startup funding rounds. Filter by therapeutic segment, funding stage, geography, and time period. Returns structured deal data with optional pipeline verification links.
| Parameter | Type | Required | Description |
|---|---|---|---|
| segment | string | required | Therapeutic area: "mRNA", "siRNA", "RNA editing", "digital health", "medtech" |
| stage | string | optional | Funding stage: "Seed", "Series A", "Series B", "Series C+", "IPO" |
| period | string | optional | Time range: "last 30 days", "last 90 days", "last 12 months", "2025", "2026" |
| geography | string | optional | Region filter: "US", "EU", "APAC", "global" |
| verify_pipeline | boolean | optional | Auto-verify pipeline claims against ClinicalTrials.gov. Default: true |
| limit | integer | optional | Max results to return. Default: 20, Max: 100 |
Cross-reference a company's claimed clinical pipeline against ClinicalTrials.gov. Detects discrepancies between pitch deck claims and registered trials. This is the killer feature — no other deal intelligence tool offers this.
| Parameter | Type | Required | Description |
|---|---|---|---|
| company | string | required | Company name or ClinicalTrials.gov sponsor name |
| claimed_programs | integer | optional | Number of programs claimed in pitch materials. If provided, enables discrepancy detection. |
| indications | string[] | optional | Specific indications to verify |
Map active healthcare investors by therapeutic segment. Identify repeat investors, total capital deployed, and clinical focus areas. Essential for founders seeking relevant VCs and for VCs doing competitive landscape analysis.
| Parameter | Type | Required | Description |
|---|---|---|---|
| segment | string | required | Therapeutic area to map investors for |
| period | string | optional | Time range for investment activity. Default: "last 12 months" |
| min_investments | integer | optional | Minimum deal count to qualify as active. Default: 1 |
| investor_type | string | optional | "VC", "CVC", "family_office", "all" |
Get anonymized peer benchmarks for healthcare startups. Median valuations, team sizes, pipeline depth, and typical investors at each funding stage. Data that costs $25K+/year on PitchBook — through a single agent query.
| Parameter | Type | Required | Description |
|---|---|---|---|
| segment | string | required | Therapeutic area for peer comparison |
| stage | string | required | Funding stage to benchmark against |
| metrics | string[] | optional | Specific metrics: "valuation", "team_size", "pipeline", "investors", "all" |
Monitor a healthcare company continuously. Get notified when they register new clinical trials, announce funding rounds, publish research, make key hires, or receive regulatory decisions. Replaces manual monitoring with automated, structured event feeds.
| Parameter | Type | Required | Description |
|---|---|---|---|
| company | string | required | Company name to track |
| events | string[] | optional | Event types: "trials", "funding", "publications", "hires", "regulatory", "all". Default: "all" |
| period | string | optional | Lookback period: "last 7 days", "last 30 days", "last 90 days". Default: "last 30 days" |
| alert | boolean | optional | Enable push alerts for new events. Default: false |
Get real-time regulatory intelligence filtered for your therapeutic segment. FDA guidance changes, EMA scientific advice, new requirements, approvals, and advisory committee decisions — all contextualized with impact analysis for active programs in the segment.
| Parameter | Type | Required | Description |
|---|---|---|---|
| segment | string | required | Therapeutic area: "mRNA", "siRNA", "RNA editing", "ASO", "gene therapy" |
| agencies | string[] | optional | Regulatory agencies: "FDA", "EMA", "PMDA", "NMPA". Default: ["FDA", "EMA"] |
| types | string[] | optional | Alert types: "guidance", "approval", "advisory", "requirements", "all" |
| period | string | optional | Lookback: "last 7 days", "last 30 days", "last 90 days" |
Venture.med is in private beta. Request access and we'll get you connected.
Join waitlist